{"id":"https://genegraph.clinicalgenome.org/r/5e1559a0-faba-4e85-8cf3-3f47378c6c92v1.0","type":"EvidenceStrengthAssertion","dc:description":"SLC1A3, encoding glial excitatory amino acid transporter 1 (EAAT1), was first reported in relation to autosomal dominant episodic ataxia, type 6 in 2005 (Jen et al., PMID: 16116111). This disease entity represents a spectrum of disorder, ranging from episodic migraine and hemiparesis to the more severe form characterized by ataxia, slurred speech, and seizures. Eight unique variants, most of which are missense, have been reported in humans. Evidence supporting this gene-disease relationship includes case-level data and experimental data.\nVariants in this gene have been reported in at least eight probands in eight publications (PMIDs: 27829685, 16116111, 29062094, 19139306, 29208948, 29066757, 32754645, 25497598). Functional studies performed on the seven observed missense variants demonstrate several possible pathogenic mechanisms depending on the mutation, with the most severe variants (p.M128R, p.P290R, and p.T318A) causing a gain-of-function altered glutamate transport and anion channels. Other variants usually cause increased amounts of transcribed protein for similar effectiveness to WT, indicating a haploinsufficency defect in glutamate uptake and anion currents (Chivukula et al., PMID: 32741053). Of note, this gene has also been implicated in Tourette syndrome and ADHD/Autism susceptibility (PMIDs: 21233784, 27296938). These will be assessed separately\nThis gene-disease association is supported primarily by a knock-in mouse model of the most characterized variant P290R which recapitulated the phenotypes of the human disorder. Several instances of functional evidence have also been characterized, with a knock-out model organism demonstrating altered glutamate transport and motor/neurological phenotypes as well as a thorough functional characterization of six missense variants in HEK293 cells.\nIn summary, SLC1A3 is definitively associated with autosomal dominant episodic ataxia. Although more published genetic evidence would allow for further characterization, the large amount of experimental data available provides important evidence towards its pathogenicity.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/5e1559a0-faba-4e85-8cf3-3f47378c6c92","GCISnapshot":"https://genegraph.clinicalgenome.org/r/3bcae41b-3438-4e82-8f29-83cca7f142f0","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/3bcae41b-3438-4e82-8f29-83cca7f142f0_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10011","date":"2020-11-03T19:50:08.579Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/3bcae41b-3438-4e82-8f29-83cca7f142f0_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10011","date":"2020-10-09T16:00:00.000Z","role":"Approver"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3bcae41b-3438-4e82-8f29-83cca7f142f0_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3bcae41b-3438-4e82-8f29-83cca7f142f0_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ab0ee4b3-738d-4c86-9d92-79b63d51a223","type":"EvidenceLine","dc:description":"This knock-in of a known pathogenic human variant model clearly recapitulates the important phenotypes of the Episodic Ataxia Type 6, with seizures, ataxia, and migraine neurological signs all being observed in these organisms. The authors also provide further investigation into the pathogenic mechansim, supporting a gain-of-function with increased anion currents leading to Bergmann glia cell degeneration and apoptosis. As this model recapitulates both the phenotypes and likely mechanism of the human disorder, it receives increased points.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b9338884-3ed7-407a-bb6f-2a932447ef95","type":"Finding","dc:description":"The first set of mutant knock-in mice were subject to generalized seizures and death before the weaning period, requiring a backcross onto the 129/SvJ strain in order to reduce lethal seizure activity and delay the onset. Even so, mutant mice demonstrated significant phenotypes indicative of human Episodic Ataxia including epilepsy, ataxia, and reduced motor/gait coordination. In order to determine the pathogenc mechanism, cerebellar Bergmann glia cells were examined to find a pronounced age-dependent reduction of cell numbers between P10 and P20. Immunostaining showed decreased numbers of somata and expression, demonstrating that the EAAT1 mutants were subject to cell death. Granule cell migration was also impaired during development, coupled with invasion of reactive astrocytes into the molecular layer demonstrating attempted repair. Following from this change, Purkinje neurons were examined and found to have been reduced and the morphology altered in mutant mice. As the P290R variant is known to increase EAAT1 anion currents in heterologous expression systems, measurement of these currents in mouse Bergmann glia cells showed significantly increased current, decreased Cl- concentration, and a resulting higher TUNEL expression in these cells, indicating earlier apoptosis events of these cell types. Spiking activities and developmental acceleration is absent in these cell types, likely due to progressive deterioration. This was verified by an observation of cerebellar size, where mutant cerebellar tissue showed generalized degeneration compared to the WT mice.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32954283","rdfs:label":"SLC1A3 Knock-In Mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":3}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/3bcae41b-3438-4e82-8f29-83cca7f142f0_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/11949ca5-65c3-4939-bfe1-81e293e5d951","type":"EvidenceLine","dc:description":"Each of these variants demonstrated altered function of some fashion when observed in HEK293 cells. Some of the more severe variants positively or negatively impacted both glutamate transport and anion currents, with others causing an increased expression pattern indicative of partially impaired glutamate transport at normal levels. Therefore, this evidence earns default points.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/73d89e3e-f614-46aa-b885-a2f5637e3dce","type":"FunctionalAlteration","dc:description":"When the WT and mutant cDNAs were expressed in HEK293 cells, cellular expression was examined for all mutants. The A329T, V393I, R499Q, and T318A variants all increased protein expression by a factor of 1.6-2x WT, indicating that without this abnormal expression glutamate uptake would be impaired and reduced in probands. T318A showed increased glutamate uptake while M128R showed an almost ccomplete disappearance of transport, with either imbalance possibly related to neurological symptoms. When cells were exposed to various voltage levels, M128R abolished anion currents in the presence of glutamate with the T318A currents being slightly larger.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32741053","rdfs:label":"SLC1A3 Variant Functional Consequences"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/1091513e-9fd6-4e3c-921a-f2c99a297ffb","type":"EvidenceLine","dc:description":"Disruption of the GLAST gene, aka the human SLC1A3 gene, caused a combination of the expected reduced glutamate uptake in the mouse line. Additionally, this loss-of-function affected both motor coordination and response to cerebellar injury. Therefore, this functional alteration evidence earns default points.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7ec99df8-058d-4fca-8943-f62610688b5b","type":"FunctionalAlteration","dc:description":"Glutamate uptake in cerebellar crude synaptosomes of mutant mice was decreased to 57.3% of that in synaptosomes from wildâ€type mice. Aditionally, when GLAST-KO mice were tested for motor coordination on the rotorod test, they consistently failed to stay on the rotating rod at 20 r.p.m. compared to the WT mice, indicating some loss of motor function. Additionally, when brain oedema developed after cold injury in both mutant and WT mice, the mutant cerebella oedema size was 4x that of the WT indicating that GLAST is integral for preventing neuronal injury after traumatic cerebellar injury.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9753165","rdfs:label":"SLC1A3 KO Mice Show Altered Glutamate and Coordination"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/3bcae41b-3438-4e82-8f29-83cca7f142f0_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9caa8f72-94c3-4118-ba52-d7434ec55d79","type":"EvidenceLine","dc:description":"As glutamate levels and transport are integral to proper neurological function and disruption can be a key factor in many neurodegenerative diseases, this evidence earns the maximum 2.0 points.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9ad4765d-94ae-4f48-85ba-aad141e2e9e8","type":"Finding","dc:description":"Glutamate is well-known as an essential neurotransmitter in the central nervous system, with any alterations in levels or transport having detrimental effects on brain function that could explain the episodic seizures, ataxia, hemiplegia, and migraines that are observed in human probands. PMID: 17517448 reviews the importance of properly functioning glutamate transporters for neurological function, including involvement in many other diseases with neurological involvement such as ALS, Huntingtons's disease, and epilepsy. This reflects the vital role glutamate takes in this system.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8123008","rdfs:label":"SLC1A3 as a Glutamate Transporter and Anion Channeler","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/d1f4096f-efe1-47e0-a7de-d1ae5929e99e","type":"EvidenceLine","dc:description":"As there is unique expression of the EAAT1 transporter localized to all areas of the brain, specifically supporting the neurological function, this evidence earns default points.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/61e6a474-1408-4ad0-8da7-16873fcd5d5c","type":"Finding","dc:description":"Northern blot analysis of RNAs from a variety of human tissues was performed to characterize the expression of each glutamate transporter. Hybridization with an EAAT1 probe revealed RNA expression in all five surveyed areas of the brain tissue, but also in some other unrelated tissues such as the heart and muscle. Human Protein Atlas agrees that there is minimal expression of RNA in several human tissues, however there is no recorded expression of EAAT1 protein itself anywhere except all areas of the brain (specifically the cerebral cortex and cerebellum).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32954283","rdfs:label":"EAAT1 mRNA and Protein Expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6},{"id":"https://genegraph.clinicalgenome.org/r/3bcae41b-3438-4e82-8f29-83cca7f142f0_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3bcae41b-3438-4e82-8f29-83cca7f142f0_ad_dn_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3f06236c-a4aa-4e96-94c4-b911407f0ecb_proband_score_evidence_line","type":"EvidenceLine","dc:description":"A confirmed de novo variant without variant-level evidence yields decreased points.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/10c697ab-5db0-4ccf-862d-943f71ac7e11","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29208948","rdfs:label":"IW","ageType":"AgeAtReport","ageUnit":"Years","ageValue":10,"detectionMethod":"Genomic DNA was isolated from peripheral blood leukocytes and subject to whole exome sequencing. Variants were filtered according to likely pathogenicity and presence in previously reported causative genes associated with ataxia, cerebellar atrophy, and other neurodegenerative diseases.The SLC1A3 variant was confirmed via Sanger seuqencing in the proband and absent in her parents.","phenotypeFreeText":"Hypoperfusion of cerebellum and brainstem at 8 yrs","phenotypes":["obo:HP_0002080","obo:HP_0002078","obo:HP_0000486","obo:HP_0001350"],"previousTesting":true,"previousTestingDescription":"Treatment with acetazolamide helped with symptoms","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/3f06236c-a4aa-4e96-94c4-b911407f0ecb_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29208948","allele":{"id":"https://genegraph.clinicalgenome.org/r/cd6c56d7-1708-4e13-9871-9b44a195870d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004172.5(SLC1A3):c.383T>G (p.Met128Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA359477326"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes"}}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/50c4d022-b2c3-4755-a8ec-5feba3f7e6bd_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This proband has ample phenotypic evidence and a heterozygous de-novo missense variant with multiple pieces of variant-level evidence (Uptake assays using glutamate demonstrated a markedly reduced glutamate uptake in mutant cells compared to the controls; coexpression studies to model the heterozygous state of the mutant demonstrated a dominant-negative effect; this variant causes an increase in SLC1A3 anion currents in both the presence and absence of glutamate, causing a gain-of-function effect in anion channel function) yields an elevated 2.5 points.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/82353aae-e934-47ed-9363-35e47749a59d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16116111","rdfs:label":"JE","ageType":"AgeAtReport","ageUnit":"Years","ageValue":10,"detectionMethod":"DNA was extracted from blood samples. All exons and flanking intronic regions of SLC1A3 were PCR-amplified and directly sequenced. These were confirmed via resequencing.","phenotypeFreeText":"Left visual field neglect, Episodic left hemifield distortion","phenotypes":["obo:HP_0002131","obo:HP_0011182","obo:HP_0002078","obo:HP_0007772","obo:HP_0011289","obo:HP_0004374","obo:HP_0001272","obo:HP_0002181","obo:HP_0001289","obo:HP_0002076","obo:HP_0045084","obo:HP_0001270","obo:HP_0002381","obo:HP_0001350","obo:HP_0010547","obo:HP_0001319","obo:HP_0007034"],"previousTesting":true,"previousTestingDescription":"Previously screened for CACNA1A and ATP1A2 with negative results; Episodic migraine attacks led to progressive right-sided headache and left-sided symptoms such as weakness and visual field neglect; Comprehensive metabolic workup revealed no abnormality in the CSF, serum, and urine; MRI showed a diffuse right-sided cortical hyperintensity most prominent in fluid-attenuated inversion recovery (FLAIR); EEG showed subclinical seizure activity in the left frontal temporal cortex and diffuse slowing on the right","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/50c4d022-b2c3-4755-a8ec-5feba3f7e6bd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16116111","allele":{"id":"https://genegraph.clinicalgenome.org/r/d14c0b86-c2e0-484e-b107-51f9099fb7fe","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004172.5(SLC1A3):c.869C>G (p.Pro290Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA254816"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2.5}],"specifiedBy":"GeneValidityOverallAutosomalDominantDeNovoVariantEvidenceCriteria","strengthScore":3.5},{"id":"https://genegraph.clinicalgenome.org/r/3bcae41b-3438-4e82-8f29-83cca7f142f0_ad_null_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/247236fa-1819-41f7-852e-725d6e069f6d_proband_score_evidence_line","type":"EvidenceLine","dc:description":"A predicted null frameshift variant without variant-level evidence yields reduced points.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3951337a-ced3-48e2-aed2-7630ab848ad2","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32754645","rdfs:label":"PAII-1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":18,"detectionMethod":"Targeted genotyping analysis was performed.","phenotypes":["obo:HP_0040292","obo:HP_0006855","obo:HP_0006744","obo:HP_0003401","obo:HP_0000640","obo:HP_0001251","obo:HP_0000147","obo:HP_0002083"],"previousTesting":true,"previousTestingDescription":"Episodes triggered by menstruation but also by stress and preceded by a sensorimotor march; EEG and electroneurography were normal; Pathologic CAG expansions in CACNA1A and conventional mutations in CACNA1A, ATP1A2, and SCN1A were ruled out; Treatment with ACZ (250 mg twice daily) prevented hemiplegic spells and interictal GEN receded; MRS demonstrated low combined glutamate and glutamine peak that responded to ACZ treatment during an episode","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/247236fa-1819-41f7-852e-725d6e069f6d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32754645","allele":{"id":"https://genegraph.clinicalgenome.org/r/0f0a17ba-6f26-4231-97fb-5039bc875e93","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004172.5(SLC1A3):c.379_383del (p.Tyr127AspfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1139532263"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallAutosomalDominantNullVariantEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/3bcae41b-3438-4e82-8f29-83cca7f142f0_ad_other_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4f589c67-66b0-4dba-9903-ed458e4234f7_proband_score_evidence_line","type":"EvidenceLine","dc:description":"A proband with sufficent phenotypic evidence and a missense variant with several pieces of variant-level evidence (WT generated robust currents in K+ solution while no currents were observed in the T387P cells, thereby impairing glutamate transport; mutant causes absence of transport, anion currents and capacitive currents upon glutamate application with little difference in a Na+ environment; both types localized to the surface membrane, but there was a lower protein expression level for the mutant as opposed to the WT) yields elevated points.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/be908d62-b9b4-4910-a485-49f8afad63c0","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29066757","rdfs:label":"KO","ageType":"AgeAtReport","ageUnit":"Years","ageValue":22,"detectionMethod":"All exons and exon-intron boundaries of the SLC1A3 gene were seuqenced and a variant was found that segregates with the phenotype.","phenotypeFreeText":"Mechanosensitivity","phenotypes":["obo:HP_0011288","obo:HP_0002017","obo:HP_0004302","obo:HP_0002076","obo:HP_0000505","obo:HP_0003474","obo:HP_0012229","obo:HP_0002321","obo:HP_0000622","obo:HP_0001269","obo:HP_0002357"],"previousTesting":true,"previousTestingDescription":"Responsive to treatment with ibuprofen; Mild head trauma is a trigger; Neuroimaging during attacks was normal; Screen for variants in CACNA1A, ATP1A2, SCN1A, and PRRT2 was negative","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/4f589c67-66b0-4dba-9903-ed458e4234f7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29066757","allele":{"id":"https://genegraph.clinicalgenome.org/r/c02b6e82-44f1-49bd-9f3a-3c2bc79855aa","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004172.5(SLC1A3):c.1159A>C (p.Thr387Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA359482299"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/637fc7b4-e419-4d40-947b-ece811f8506a_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Although phenotypic and variant-level evidence provide support (PMID: 32741053 asserted that changes in uptake nor anion currents were observed, however expression levels were significantly increased), the relatively high presence in gnomAD (0.0001471, https://gnomad.broadinstitute.org/variant/5-36686238-G-A) plus the lack of conclusive evidence for this variant yields minimal points.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0e6359d0-e41d-477c-8739-b2060c2017f0","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25497598","rdfs:label":"PY17","ageType":"AgeAtReport","ageUnit":"Years","ageValue":30,"detectionMethod":"Blood genomic DNA was enriched and whole exome sequenced. Alightment to hg19 and variant filtering was performed with putative pathogenic variants being confirmed via Sanger sequencing.","phenotypes":"obo:HP_0000571","previousTesting":true,"previousTestingDescription":"Underwent brain MRI and CSF examination with oligoclonal band analysis; Negative genetic testing for SCA1, 2, 3, 6, 7, 17 (now known as ATXN1, ATXN2, CACNA1A, ATXN7, and TBP, respectively), DRPLA (now known as ATN1), FA (now known as FXN) and FMR1","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/637fc7b4-e419-4d40-947b-ece811f8506a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25497598","allele":{"id":"https://genegraph.clinicalgenome.org/r/272468bc-051b-4920-beef-67e3e6e46cf0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004172.5(SLC1A3):c.1496G>A (p.Arg499Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3235696"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/e1b137ba-0f71-4578-a289-024c05c2d568_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Although this proband does display the phenotypic signs of episodic ataxia type 6, the high MAF of this variant in gnomAD (0.002656, https://gnomad.broadinstitute.org/variant/5-36679820-A-G) provides enough doubt that this proband is not scored.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/95a88950-c9ec-46b9-9c6f-be80a7328dd4","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29062094","rdfs:label":"KDC23","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":38,"detectionMethod":"Next-generation sequencing was perfomed on all probands with 40 candidate genes and five known EA genes.","phenotypes":["obo:HP_0000640","obo:HP_0002131","obo:HP_0011477","obo:HP_0001260","obo:HP_0002321","obo:HP_0100543"],"previousTesting":true,"previousTestingDescription":"Negtive response to acetazolamide","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/e1b137ba-0f71-4578-a289-024c05c2d568_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29062094","allele":{"id":"https://genegraph.clinicalgenome.org/r/c3de76b4-1f67-45c0-989c-3b3a28b7d0d3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004172.5(SLC1A3):c.952A>G (p.Thr318Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3235581"}}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/1200edbf-8d2f-4d7a-bb21-219d251438d2_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Although this proband and another family member does display the phenotypic signs of episodic ataxia type 6, the high MAF of this variant in gnomAD (0.0002940, https://gnomad.broadinstitute.org/variant/5-36680579-G-A) and the inconsistent segregations provide enough doubt that this proband is not scored.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/18b1dd47-6a11-4494-85fa-33980a081e47","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27829685","rdfs:label":"KDCII-4","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":55,"detectionMethod":"Genomic DNA was extracted fom patient blood samples. Whole exome sequencing was performed. Sequence variants in KCNA1, CACNA1A, CACNB4 and SLC1A3 were all searched with pathogenicity-based variant filtering. The found variant was further confirmed via PCR and Sanger sequencing.","phenotypes":["obo:HP_0010545","obo:HP_0001260","obo:HP_0002078","obo:HP_0000651","obo:HP_0001350","obo:HP_0002317","obo:HP_0007338"],"previousTesting":true,"previousTestingDescription":"Ataxic episodes usually caused by stress, heat, or smoking; Normal brain MRI; No pathogenic mutations causing spinocerebellar ataxia","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/1200edbf-8d2f-4d7a-bb21-219d251438d2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27829685","allele":{"id":"https://genegraph.clinicalgenome.org/r/902c1d1d-daba-4ab9-8d59-f6a885435cdb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004172.5(SLC1A3):c.1177G>A (p.Val393Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3235626"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/58405acd-772b-4fd8-b300-7b34e9dcec9d_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Sufficent phenotypic evidence plus a missense variant with variant-level evidence (Radioactive glutamate uptake assays in COS7 cells showed an 18% reduction in glutamate uptake in the mutant cells compared to the controls (88.2 +/- 5.5 pmol/mg protein VS 107.8 +/- 6.9 pmol/mg protein)) yields default points.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d960699a-0d46-4412-bd0d-6ffc774ec755","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19139306","rdfs:label":"DEVRIII-3","ageType":"AgeAtReport","ageUnit":"Years","ageValue":35,"detectionMethod":"Genomic DNA was isolated from peripheral leukocytes. All exons and flanking introns of the SLC1A3 gene were amplified and sequenced. Restriction digest verified the results.","phenotypes":["obo:HP_0007979","obo:HP_0000651","obo:HP_0000622","obo:HP_0001350"],"previousTesting":true,"previousTestingDescription":"Attacks were generally triggered by emotional stress, with some triggered by fatigue; Acetazolamide significantly reduced the frequency of attacks in all 3 affected family members; Interictal electroencephalographic recording revealed no epileptic activity, and magnetic resonance imaging revealed no abnormalities; Attacks were provoked by emotional stress, fatigue, or consuming alcohol or caffeine","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/58405acd-772b-4fd8-b300-7b34e9dcec9d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19139306","allele":{"id":"https://genegraph.clinicalgenome.org/r/bd536960-4435-4b54-b5c9-3c9e90e26ce5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004172.5(SLC1A3):c.556T>A (p.Cys186Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA254817"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallAutosomalDominantOtherVariantEvidenceCriteria","strengthScore":1.6},{"id":"https://genegraph.clinicalgenome.org/r/3bcae41b-3438-4e82-8f29-83cca7f142f0_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7cab7b4f-ce90-47e8-80fa-7ea3506f693e_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough evidence","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27829685","rdfs:label":"KDC","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/7cab7b4f-ce90-47e8-80fa-7ea3506f693e","type":"Family","rdfs:label":"KDC","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/18b1dd47-6a11-4494-85fa-33980a081e47"}},"meetsInclusionCriteria":false,"phenotypeFreeText":"","phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0001251","obo:HP_0002018","obo:HP_0002321"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/18b1dd47-6a11-4494-85fa-33980a081e47"}},{"id":"https://genegraph.clinicalgenome.org/r/0b711b0d-0b88-4ca7-a62d-7ed99f8d5be0_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough info","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19139306","rdfs:label":"DEVR","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/0b711b0d-0b88-4ca7-a62d-7ed99f8d5be0","type":"Family","rdfs:label":"DEVR","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/d960699a-0d46-4412-bd0d-6ffc774ec755"}},"meetsInclusionCriteria":false,"phenotypeFreeText":"","phenotypePositiveAllelePositive":4,"phenotypes":["obo:HP_0000613","obo:HP_0002183","obo:HP_0002017","obo:HP_0002078","obo:HP_0002321","obo:HP_0000639","obo:HP_0002066"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/d960699a-0d46-4412-bd0d-6ffc774ec755"}},{"id":"https://genegraph.clinicalgenome.org/r/487a402d-788e-48c8-8457-4424b80fd4b8_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough segregations","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25497598","rdfs:label":"PY","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/487a402d-788e-48c8-8457-4424b80fd4b8","type":"Family","rdfs:label":"PY","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/0e6359d0-e41d-477c-8739-b2060c2017f0"}},"meetsInclusionCriteria":false,"phenotypeFreeText":"","phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0008003","obo:HP_0030453","obo:HP_0001260","obo:HP_0002131"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/0e6359d0-e41d-477c-8739-b2060c2017f0"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":6.1}],"evidenceStrength":"Definitive","sequence":1427,"specifiedBy":"GeneValidityCriteria7","strengthScore":12.1,"subject":{"id":"https://genegraph.clinicalgenome.org/r/nZ9rKH-HVls","type":"GeneValidityProposition","disease":"obo:MONDO_0012982","gene":"hgnc:10941","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_3bcae41b-3438-4e82-8f29-83cca7f142f0-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}